Abstract
A guidance on the assessment and treatment of postmenopausal women at risk from fractures due to osteoporosis was recently published in Osteoporosis International as a joint effort of the International Osteoporosis Foundation and European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (Kanis et al. in Osteoporos Int https://doi.org/10.1007/s00198-018-4704-5, 2018). This manuscript updates the previous guidelines document, published in 2013 (Kanis et al. in Osteoporos Int 24:23–57, 2013) and is written in a European perspective. The present article reports and summarizes the main recommendations included in this 2018 guidance document.
Similar content being viewed by others
References
Kanis JA, Cooper C, Rizzoli R, Reginster, JY on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors and the Committee of National Societies of the International Osteoporosis Foundation (IOF) (2018) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. https://doi.org/10.1007/s00198-018-4704-5
Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster J-Y on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2013). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int, 24: 23–57
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Conflict of interest
JAK reports grants from Amgen, Eli Lilly and Radius Health; non-financial support from Medimaps, and Asahi; and other support from AgNovos. JAK is the architect of FRAX® but has no financial interest. CC reports personal fees from Alliance for Better Bone Health,Amgen, Eli Lilly, GSK,Medtronic,Merck, Novartis, Pfizer, Roche, Servier, Takeda and UCB. RR has received consulting fees or advisory board fees from Radius Health, Labatec, Danone, Nestlé, CNIEL and Sandoz. J-YR has received advisory board or consulting fees from IBSA-Genévrier, Pierre Fabre, Radius Health, TEVA and Mylan; and lecture fees from Anovos, IBSA-Genévrier, Mylan, CNIEL, Dairy Research Council (DRC) and Theramex; and institutional grant support from IBSA-Genévrier, Mylan, CNIEL and Radius Health.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is co-published in the journals Aging, Clinical and Experimental Research and Calcified Tissue International, https://doi.org/10.1007/s40520-018-1109-4 and https://doi.org/10.1007/s00223-018-00512-x.
Reprinted by permission from Springer Nature Customer Service Centre Gmbh: Springer, Osteoporosis International, European guidance for the diagnosis and management of osteoporosis in postmenopausal women, A. Kanis, C. Cooper, R. Rizzoli, J.-Y. Reginster, 2018
Rights and permissions
About this article
Cite this article
Kanis, J.A., Cooper, C., Rizzoli, R. et al. Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Calcif Tissue Int 104, 235–238 (2019). https://doi.org/10.1007/s00223-018-00512-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00223-018-00512-x